Publishing: July 2021 | Report Code: LS12191 | Available Format: PDF
The global benign prostatic hyperplasia treatment market was valued around $10 billion in 2020, which is projected to grow with healthy growth rate during the forecast period (2021–2030). The major factors behind the growth of the market are the increasing aging population, rising awareness about prostate cancer and its treatment, growing technological advancements in personalized medicine, increasing adoption of minimally invasive procedures, and improving healthcare infrastructure across the world.
As a result of the COVID-19 epidemic, governments in several nations have taken strategic measures to protect citizens, such as lockdowns and social distancing. The economic crisis generated by the epidemic has had a negative impact on manufacturers across the globe, including those of BPH drugs and surgical devices. Furthermore, the availability of raw materials has been significantly affected due to the government limitations on internal and international trade to contain the spread of the virus. This further restrained the growth of the BPH treatment market by affecting the manufacturing of active pharmaceutical ingredients (APIs) due to the shortage of raw materials.
The drug treatment category had the larger share in 2020, based on type. This was majorly due to the high adoption of medicines to manage and treat the disorder at the acute and sub-acute levels. In addition, medication is prescribed for post-operative treatment, which leads to their higher consumption compared to surgical devices.
The home healthcare settings category is expected to witness the fastest growth during the forecast period in the benign prostatic hyperplasia treatment market, based on end user. This is ascribed to the rising use of drugs and devices that are used for pre-surgical treatment. In addition, patients are also prescribed medication for a few weeks after being discharged from the hospital, which is majorly consumed at homes.
Geographically, North America generated the highest revenue in the benign prostatic hyperplasia treatment market in 2020. This is mainly attributed to the increasing geriatric population, which is highly susceptible to BPH and other lower urinary tract diseases. In addition, the rising number of innovations in BPH devices, increasing awareness about the condition, and enhanced reimbursement coverage continue to boost the volume of BHP treatments in the region.
Surgery is a better alternative to the management of BPH via medication, but patients have a higher preference for medication due to the post-operative damage to the body caused by surgical cuts and burns. The development of minimally invasive procedures has brought about a change in patients’ perception and given surgical device manufacturers a competitive edge. For instance, in August 2020, the UroLift enhanced tissue control system was developed by Teleflex Inc. to treat people with BPH. Small implants that retain the prostate lobes in a retracted position can be inserted into the system to open the urethra. The device is designed to treat patients with difficult a prostatic architecture, such as those who have big lateral lobes and an obstructive median lobe.
According to the United Nations Department of Economic and Social Affairs (UNDESA) report on the global aging population, the number of people aged 65 and above is rapidly increasing, and it would more than double by 2050. The increase in research and development (R&D) activities to treat the prostate condition, especially in the senior population, which requires additional care, have enhanced BPH treatment devices, thus supporting the worldwide benign prostatic hyperplasia treatment market advanced.
|Base Year (2020) Market Size||~$10 Billion|
|Market Size Forecast in 2030||~$17 Billion|
|Report Coverage||Market Trends; Revenue Estimation and Forecast; Segmentation Analysis; Regional Breakdown; Companies’ Strategic Developments; Product Benchmarking; Company Profiling|
|Market Size by Segments||By Type; By End User; By Region|
|Market Size of Geographies||China; India; Japan; South Korea; Australia; U.S.; Canada; Mexico; Brazil; Germany; U.K.; France; Spain; Italy; Saudi Arabia; South Africa|
|Secondary Sources and References (Partial List)||United Nations Department of Economic and Social Affairs (UNDESA); Centers for Disease Control and Prevention (CDC); International Agency for Research on Cancer (IARC); World Health Organization (WHO)|
The global market for BPH treatment has various key players, such as NeoTract Inc., NxThera Inc., Boston Scientific Corporation, Urologix LLC, Convergent Laser Technologies, Karl Storz GmbH & Co. KG, Lumenis Ltd., Olympus Corporation, Advin Urology, Richard Wolf GmbH, and Medtronic plc.
In recent years, the players in the market have engaged in product launches to offer better treatments than other competitors. For instance,
The global benign prostatic hyperplasia treatment market report offers comprehensive market segmentation analysis along with market estimation for the period 2015–2030.
Based on Type
Based on End User
The value of the global BPH treatment market will be $17 billion in 2030.
The home healthcare settings end user category held the larger share in the BPH treatment market in 2020.
The drug treatment categroy will register the faster growth, under the type segment, in the BPH treatment industry during 2021–2030.
The COVID-19 pandemic massviely hampered the growth of the market for BPH treatments.
The major trend currently being observed in the market for BPH treatments is product approvals and launches.
Get a bespoke market intelligence solution
Our dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws